Evidence map›Paper›PMID 34290694›Full record

ArticleFrontiers in immunology2021

Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes.

Caroline Spenlé, Thomas Loustau, Hélène Burckel, Gilles Riegel, Chérine Abou Faycal, Chengbei Li, Alev Yilmaz, Luciana Petti, Fanny Steinbach, Constance Ahowesso and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Preclinical models in the study of lymph node metastasis.Journal of Zhejiang University. Science. B · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Advances on the roles of tenascin-C in cancer.Journal of cell science · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Caroline SpenléINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France.
Thomas LoustauUniversité de Strasbourg, Strasbourg, France.
Hélène BurckelInstitut de Cancérologie de Strasbourg Europe (ICANS), UNICANCER, Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Université de Strasbourg, Strasbourg, France.
Gilles RiegelUniversité de Strasbourg, Strasbourg, France.
Chérine Abou FaycalUniversité de Strasbourg, Strasbourg, France.
Chengbei LiUniversité de Strasbourg, Strasbourg, France.
Alev YilmazINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France.
Luciana PettiUniversité Côte d'Azur, CNRS, IPMC, Valbonne-Sophia Antipolis, France.
Fanny SteinbachUniversité de Strasbourg, Strasbourg, France.
Constance AhowessoINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France.
Camille JostINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France.
Nicodème PaulUniversité de Strasbourg, Strasbourg, France.
Raphael CarapitoUniversité de Strasbourg, Strasbourg, France.
Georges NoëlInstitut de Cancérologie de Strasbourg Europe (ICANS), UNICANCER, Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Université de Strasbourg, Strasbourg, France.
Fabienne AnjuèreUniversité Côte d'Azur, CNRS, IPMC, Valbonne-Sophia Antipolis, France.
Nathalie SaloméUniversité de Strasbourg, Strasbourg, France.
Gertraud OrendINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France.
Inserm · FRUniversité de Strasbourg · FRCentre National de la Recherche Scientifique · FRInstitut de Cancérologie Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy, the most frequent treatment of oral squamous cell carcinomas (OSCC) besides surgery is employed to kill tumor cells but, radiotherapy may also promote tumor relapse where the immune-suppressive tumor microenvironment (TME) could be instrumental. We established a novel syngeneic grafting model from a carcinogen-induced tongue tumor, OSCC13, to address the impact of radiotherapy on OSCC. This model revealed similarities with human OSCC, recapitulating carcinogen-induced mutations found in smoking associated human tongue tumors, abundant tumor infiltrating leukocytes (TIL) and, spontaneous tumor cell dissemination to the local lymph nodes. Cultured OSCC13 cells and OSCC13-derived tongue tumors were sensitive to irradiation. At the chosen dose of 2 Gy mimicking treatment of human OSCC patients not all tumor cells were killed allowing to investigate effects on the TME. By investigating expression of the extracellular matrix molecule tenascin-C (TNC), an indicator of an immune suppressive TME, we observed high local TNC expression and TIL infiltration in the irradiated tumors. In a TNC knockout host the TME appeared less immune suppressive with a tendency towards more tumor regression than in WT conditions. Altogether, our novel syngeneic tongue OSCC grafting model, sharing important features with the human OSCC disease could be relevant for future anti-cancer targeting of OSCC by radiotherapy and other therapeutic approaches.

Indexed as

AnimalsCell Line, TumorFemaleLymphatic MetastasisLymph NodesMiceMice, Inbred C57BLMice, KnockoutMice, NudeNeoplasm TransplantationRadiation ToleranceSquamous Cell Carcinoma of Head and NeckTenascinTongue NeoplasmsTransplantation, IsogeneicTumor BurdenTenascinTnc protein, mouseimmune suppressionoral squamous carcinomaradiotherapysyngeneic animal modeltenascin-Ctumor microenvironment

Identifiers

PMID34290694
PMCPMC8287883
OpenAlexW3186222428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.